LIFEVANTAGE CORP Effective Tax Rate
LIFEVANTAGE CORP (LFVN) reported Effective Tax Rate of 16.40% for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-08-27
- LIFEVANTAGE CORP effective income tax rate reconciliation, percent for the quarter ending 2017-09-30 was 35.10%, a 18.18% increase year-over-year.
- LIFEVANTAGE CORP effective income tax rate reconciliation, percent for the quarter ending 2016-09-30 was 29.70%, a 20.80% decline year-over-year.
- LIFEVANTAGE CORP effective income tax rate reconciliation, percent for the quarter ending 2015-09-30 was 37.50%, a 9.97% increase year-over-year.
- LIFEVANTAGE CORP effective income tax rate reconciliation, percent for the quarter ending 2014-09-30 was 34.10%, a 4.21% decline year-over-year.
- LIFEVANTAGE CORP effective income tax rate reconciliation, percent for fiscal 2026 was 16.40%, a 17.59% decline from fiscal 2025.
- LIFEVANTAGE CORP effective income tax rate reconciliation, percent for fiscal 2025 was 19.90%, a 38.77% decline from fiscal 2024.
- LIFEVANTAGE CORP effective income tax rate reconciliation, percent for fiscal 2024 was 32.50%, a 10.96% decline from fiscal 2023.
- LIFEVANTAGE CORP effective income tax rate reconciliation, percent for fiscal 2023 was 36.50%, a 8.96% increase from fiscal 2022.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month | Effective Income Tax Rate Reconciliation, Percent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 16.40% 10-K · filed 2026-08-27 | ||||
| 2025-06-30 | 19.90% 10-K · filed 2026-08-27 | ||||
| 2024-06-30 | 32.50% 10-K · filed 2025-09-04 | ||||
| 2023-06-30 | 36.50% 10-K · filed 2024-08-28 | ||||
| 2022-06-30 | 33.50% 10-K · filed 2023-08-28 | ||||
| 2021-06-30 | 25.20% 10-K · filed 2022-08-23 | ||||
| 2020-06-30 | 21.20% 10-K · filed 2022-08-23 | ||||
| 2019-06-30 | 19.50% 10-K · filed 2021-08-19 | ||||
| 2018-06-30 | 39.70% 10-K · filed 2020-08-18 | ||||
| 2018-03-31 | 50.10% 10-Q · filed 2018-05-09 | ||||
| 2017-12-31 | 65.80% 10-Q · filed 2018-02-07 | ||||
| 2017-09-30 | 35.10% 10-Q · filed 2018-02-07 | ||||
| 2017-06-30 | 44.70% 10-K · filed 2019-08-14 | ||||
| 2017-03-31 | 29.10% 10-Q · filed 2017-05-10 | ||||
| 2016-12-31 | 30.00% 10-Q · filed 2017-02-08 | ||||
| 2016-09-30 | 29.70% 10-Q · filed 2016-12-12 | ||||
| 2016-06-30 | 29.70% 10-K · filed 2018-08-15 | 30.70% 10-K · filed 2016-12-12 | |||
| 2016-03-31 | 37.80% 10-Q/A · filed 2016-07-19 | ||||
| 2015-12-31 | 35.40% 10-Q · filed 2016-02-09 | ||||
| 2015-09-30 | 37.50% 10-Q · filed 2015-11-04 | ||||
| 2015-06-30 | 33.10% 10-K · filed 2017-09-07 | 34.40% 10-K · filed 2015-09-01 | |||
| 2015-03-31 | 32.00% 10-Q · filed 2015-05-06 | ||||
| 2014-12-31 | 32.90% 10-Q · filed 2015-02-04 | ||||
| 2014-09-30 | 34.10% 10-Q · filed 2014-11-06 | ||||
| 2014-06-30 | 31.50% 10-K · filed 2016-12-12 | ||||
| 2014-03-31 | 31.00% 10-Q · filed 2014-05-06 | ||||
| 2013-12-31 | 34.00% 10-Q · filed 2014-02-06 | ||||
| 2013-09-30 | 35.60% 10-Q · filed 2013-11-07 | ||||
| 2013-06-30 | 31.70% 10-K · filed 2015-09-01 | 31.71% 10-K · filed 2013-09-12 | |||
| 2013-03-31 | 35.36% 10-Q · filed 2013-05-09 | ||||
| 2012-12-31 | 39.63% 10-Q · filed 2013-02-07 | ||||
| 2012-09-30 | 38.99% 10-Q · filed 2012-11-08 | ||||
| 2012-06-30 | 16.00% 10-K · filed 2014-09-10 | 16.04% 10-K · filed 2012-09-10 | |||
| 2011-06-30 | -0.18% 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |